[wpml_language_selector_widget]

Understanding DEEs

Developmental and epileptic encephalopathies—or DEEs—are seizure disorders that are often treatment-resistant. They most often begin in infancy and are associated with seizures of long duration and major developmental delays.1 The term DEE refers to when cognitive functions are influenced by both seizure and interictal epileptiform activity and the neurobiological process behind the epilepsy.2

Developmental Encephalopathy (DE)

This term can be used for those with non-progressive diseases with cognitive impairment and co-existing epilepsy, in whom the epileptiform activity has minimal or no effect on function.2

Epileptic Encephalopathy (EE)

This term is designated for patients whose seizure activity has a direct impact on cognition, as most can revert to their normal or near normal baseline cognitive state with effective treatment.2

DEEs are rare and also challenging to diagnose and treat effectively. They include, but are not limited to the conditions and syndromes listed below:1

  • Lennox-Gastaut Syndrome
  • Dravet Syndrome
  • Tuberous Sclerosis Complex
  • Epilepsy of Infancy with Migrating Focal Seizures (EIMFS)
  • Infantile Spasms Syndrome (ISS)
  • Gelastic Seizures with Hypothalamic Hamartoma
  • Myoclonic-Atonic Epilepsy
  • Lafora Disease
  • Several Etiology-Specific Syndromes (eg, KCNQ2, CDKL5, PCDH19, etc)

Epilepsies that begin in childhood and persist into adulthood may also result in major challenges in the transition to adult care, including in the management of psychiatric disorders, migraine, movement disorders, and spasticity. Consideration of these disease sequelae must be evaluated early on in the disease course, and throughout the patient’s life.3,4

References

  1. Epilepsy Foundation. Developmental and Epileptic Encephalopathy (DEE). March 1, 2021. Accessed August 17, 2024. https://www.epilepsy.com/what-is-epilepsy/syndromes/developmental-and-epileptic-encephalopathy
  2. Raga S, Specchio N, Rheims S, Wilmshurst JM. Developmental and epileptic encephalopathies: Recognition and approaches to care. Epileptic Disord. 2021;23:40-52. doi:10.1684/epd.2021.1244
  3. Berg AT, Kaiser K, Dixon-Salazar T, et al. Seizure burden in severe early-life epilepsy: Perspectives from parents. Epilepsia Open. 2019;4:293-301. doi:10.1002/epi4.12319
  4. Scheffer IE, Dravet C. Transition to adult life in the monogenic epilepsies. Epilepsia. 2014;55(suppl 3):12-15. doi:10.1111/epi.12707

Pin It on Pinterest

Scroll to Top

You are now leaving the THRIVE site

The THRIVE Neuroscience Community of Care site is funded by an independent medical education grant from Jazz Pharmaceuticals. The following site is not affiliated with the THRIVE educational initiative and MLG is not responsible for its content.

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers